Avondale, PA, United States of America

Bhavnish Parikh

This inventor holds 19 USPTO granted patents and 8 published patent applications, plus 3 CIPO patents and 3 EPO patents, primarily in JAK Inhibitor Formulations. Top assignees: Incyte Corporation, Incyte Holdings Corporation, Incyte Holdings Comoration. Active years: 2017-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bhavnish Parikh. Retrieved from https://idiyas.com/inventor/bhavnish-parikh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 3.7

ph-index = 9

Forward Citations = 173(Granted Patents)


Company Filing History:


Years Active: 2017-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Topical Formulation
JAK Inhibitor
Sustained Release
Ruxolitinib
Dosage Forms
Pharmaceuticals
Drug Delivery
Therapeutics
Inhibitor Formulation
JAK1
Chronic Conditions
Skin Treatments
19 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Bhavnish Parikh

Introduction

Bhavnish Parikh is a notable inventor based in Avondale, PA, who has made significant contributions to the field of pharmaceuticals. With a total of 16 patents to his name, he has focused on developing innovative formulations and dosage forms that address various skin disorders and other medical conditions.

Latest Patents

Among his latest inventions is a topical formulation for a JAK inhibitor. This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and its use in the treatment of skin disorders. Another significant patent is for sustained release dosage forms for a JAK1 inhibitor. This invention involves sustained release dosage forms comprising {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof, along with related doses and methods.

Career Highlights

Bhavnish Parikh has worked with prominent companies in the pharmaceutical industry, including Incyte Corporation and Incyte Holdings Corporation. His work has contributed to advancements in drug formulations and therapeutic applications, showcasing his expertise and dedication to innovation.

Collaborations

Throughout his career, Bhavnish has collaborated with talented individuals such as Krishnaswamy Yeleswaram and Yong Ni. These collaborations have further enhanced his research and development efforts, leading to impactful inventions.

Conclusion

Bhavnish Parikh's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through inventive solutions. His patents reflect a deep understanding of complex medical challenges and a drive to create effective treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…